These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 17319458)

  • 41. Macrovascular complications of metabolic syndrome: an early intervention is imperative.
    Tenenbaum A; Motro M; Schwammenthal E; Fisman EZ
    Int J Cardiol; 2004 Nov; 97(2):167-72. PubMed ID: 15458679
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of type IIb dyslipidemia.
    Arai H; Ishibashi S; Bujo H; Hayashi T; Yokoyama S; Oikawa S; Kobayashi J; Shirai K; Ota T; Yamashita S; Gotoda T; Harada-Shiba M; Sone H; Eto M; Suzuki H; Yamada N;
    J Atheroscler Thromb; 2012; 19(2):105-14. PubMed ID: 22139432
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mannose-binding lectin in obesity with different degrees of metabolic syndrome abnormalities: association with atherogenic and metabolic traits.
    Strack C; Baessler A; Wagner F; Bruxmeier J; Yaroslavskii O; Rousseva E; Loew T; Riegger G; Schmitz G; Fischer M
    J Atheroscler Thromb; 2012; 19(6):539-51. PubMed ID: 22472212
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD.
    Eckel RH
    Proc Nutr Soc; 2007 Feb; 66(1):82-95. PubMed ID: 17343775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug treatment of metabolic syndrome.
    Altabas V
    Curr Clin Pharmacol; 2013 Aug; 8(3):224-31. PubMed ID: 22950955
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Preventing cardiovascular and renal complications in the management of hypertension and metabolic syndrome.
    Chen J; Townsend RR
    Expert Opin Pharmacother; 2007 Sep; 8(13):2001-9. PubMed ID: 17714054
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A major health hazard: the metabolic syndrome.
    Isomaa B
    Life Sci; 2003 Sep; 73(19):2395-411. PubMed ID: 12954449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacotherapy for the metabolic syndrome.
    Swislocki AL; Siegel D; Jialal I
    Curr Vasc Pharmacol; 2012 Mar; 10(2):187-205. PubMed ID: 22022773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics.
    Longo-Mbenza B; Nkondi Nsenga J; Vangu Ngoma D
    Int J Cardiol; 2007 Oct; 121(3):229-38. PubMed ID: 17368586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The prevalence of metabolic syndrome in middle-aged in Kaunas population].
    Gustiene O; Slapikas R; Klumbiene J; Sakalauskiene G; Kubilius R; Bagdzeviciūte S; Zaliūnas R
    Medicina (Kaunas); 2005; 41(10):867-76. PubMed ID: 16272835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dietary interventions in the treatment of metabolic syndrome as a cardiovascular disease risk-inducing factor. A review.
    Mandecka A; Regulska-Ilow B
    Rocz Panstw Zakl Hig; 2018; 69(3):227-233. PubMed ID: 30141315
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nutrapharmacology of tocotrienols for metabolic syndrome.
    Weng-Yew W; Brown L
    Curr Pharm Des; 2011; 17(21):2206-14. PubMed ID: 21774781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic syndrome and other factors associated with increased risk of diabetes.
    Streja D
    Clin Cornerstone; 2004; 6 Suppl 3():S14-29. PubMed ID: 15707266
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic syndrome, glucose tolerance categories and the cardiovascular risk in Spanish population.
    Martínez-Larrad MT; Corbatón-Anchuelo A; Fernández-Pérez C; Lazcano-Redondo Y; Escobar-Jiménez F; Serrano-Ríos M
    Diabetes Res Clin Pract; 2016 Apr; 114():23-31. PubMed ID: 27103365
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Obesity and metabolic phenotypes (metabolically healthy and unhealthy variants) are significantly associated with prevalence of elevated C-reactive protein and hepatic steatosis in a large healthy Brazilian population.
    Shaharyar S; Roberson LL; Jamal O; Younus A; Blaha MJ; Ali SS; Zide K; Agatston AA; Blumenthal RS; Conceição RD; Santos RD; Nasir K
    J Obes; 2015; 2015():178526. PubMed ID: 25838943
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of the metabolic syndrome.
    Hafidh S; Senkottaiyan N; Villarreal D; Alpert MA
    Am J Med Sci; 2005 Dec; 330(6):343-51. PubMed ID: 16355020
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation.
    Poznyak A; Grechko AV; Poggio P; Myasoedova VA; Alfieri V; Orekhov AN
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.